Fat Cell Injection for Knee Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests if injecting special cells from a patient's own fat can reduce pain and improve function in people with knee osteoarthritis. These cells have been investigated in various studies for their potential to treat knee osteoarthritis by reducing pain and improving function.
Will I have to stop taking my current medications?
Yes, you will need to stop taking prescription or over-the-counter pain medications 7 days before any visit, except for the Day 2 Post Treatment Visit. Additionally, certain blood thinners and anti-inflammatory medications must be stopped for a specified period before the injection.
Is fat cell injection for knee osteoarthritis safe?
How is the treatment using autologous adipose-derived stromal vascular fraction for knee osteoarthritis different from other treatments?
This treatment is unique because it uses a patient's own fat cells, specifically the stromal vascular fraction (SVF), which is injected directly into the knee joint. It is believed to work by interacting with the knee's fat tissue to regulate inflammation and promote healing, offering a novel approach compared to traditional treatments like pain relievers or surgery.12346
Who Is on the Research Team?
William Cimino, PhD
Principal Investigator
GID BIO
Are You a Good Fit for This Trial?
This trial is for men and women aged 35-85 with knee osteoarthritis who've tried at least two treatments without success, including physical therapy or injections. They must not have had recent major knee injuries, surgery, or certain other joint conditions. Participants need to understand English, be able to attend follow-up visits, and have a BMI between 22 and 37.Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single injection of either placebo or autologous adipose-derived SVF for treatment of knee osteoarthritis
Follow-up
Participants are monitored for safety and effectiveness after treatment, with primary efficacy measured at 12 months post-treatment
What Are the Treatments Tested in This Trial?
Interventions
- Autologous Adipose-derived Stromal Vascular Fraction
- GID SVF-2 Device System
Find a Clinic Near You
Who Is Running the Clinical Trial?
GID BIO, Inc.
Lead Sponsor